Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes

被引：0
|
作者：
Zeqing Zhang
Xi Chen
Puhan Lu
Jianhua Zhang
Yongping Xu
Wentao He
Mengni Li
Shujun Zhang
Jing Jia
Shiying Shao
Junhui Xie
Yan Yang
Xuefeng Yu
机构：
[1] Huazhong University of Science and Technology,Division of Endocrinology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College
来源：
Cardiovascular Diabetology | / 16卷
关键词：
Glucagon-like peptide-1 agonists; Dipeptidyl peptidase-4 inhibitors; Type 2 diabetes mellitus; Cardiovascular outcomes; Acute pancreatitis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes
    Zhang, Zeqing
    Chen, Xi
    Lu, Puhan
    Zhang, Jianhua
    Xu, Yongping
    He, Wentao
    Li, Mengni
    Zhang, Shujun
    Jia, Jing
    Shao, Shiying
    Xie, Junhui
    Yang, Yan
    Yu, Xuefeng
    CARDIOVASCULAR DIABETOLOGY, 2017, 16
  • [2] Cardiovascular outcomes with the incretin-based therapies GLP-1 agonists and DPP-4 inhibitors in type 2 diabetes participants with and without heart failure
    Zheng, S. L.
    Collins, P.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 : 202 - 203
  • [3] Cardiovascular outcome studies with incretin-based therapies: Comparison between DPP-4 inhibitors and GLP-1 receptor agonists
    Scheen, Andre J.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2017, 127 : 224 - 237
  • [4] Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors
    Sachinidis, Alexandros
    Nikolic, Dragana
    Stoian, Anca Pantea
    Papanas, Nikolaos
    Tarar, Omer
    Rizvi, Ali A.
    Rizzo, Manfredi
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 111
  • [5] Incretin-based drugs and the kidney in type 2 diabetes: choosing between DPP-4 inhibitors and GLP-1 receptor agonists
    Mann, Johannes F. E.
    Muskiet, Marcel H. A.
    KIDNEY INTERNATIONAL, 2021, 99 (02) : 314 - 318
  • [6] Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
    Enrico Longato
    Barbara Di Camillo
    Giovanni Sparacino
    Lara Tramontan
    Angelo Avogaro
    Gian Paolo Fadini
    Cardiovascular Diabetology, 19
  • [7] Better cardiovascular outcomes of type 2 diabetic patients treated with GLP-1 receptor agonists versus DPP-4 inhibitors in clinical practice
    Longato, Enrico
    Di Camillo, Barbara
    Sparacino, Giovanni
    Tramontan, Lara
    Avogaro, Angelo
    Fadini, Gian Paolo
    CARDIOVASCULAR DIABETOLOGY, 2020, 19 (01)
  • [8] Incretin-based medications (GLP-1 receptor agonists, DPP-4 inhibitors) as a means to avoid hypoglycaemic episodes
    Farngren, Johan
    Ahren, Bo
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2019, 99 : 25 - 31
  • [9] DPP-4 inhibitors and GLP-1 receptor agonists. Cardiovascular effects
    Nauck, M. A.
    El Aziz, M. S. Abd
    Meier, J. J.
    DIABETOLOGE, 2016, 12 (03): : 184 - +
  • [10] The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
    Secrest, Matthew H.
    Udell, Jacob A.
    Filion, Kristian B.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2017, 27 (03) : 194 - 202
12345